Salfi, Federico http://orcid.org/0000-0003-1961-286X
Amicucci, Giulia http://orcid.org/0000-0001-9975-6497
Ferrara, Michele http://orcid.org/0000-0003-2304-7576
Tempesta, Daniela http://orcid.org/0000-0002-6942-5336
De Berardinis, Andrea
Chiricozzi, Andrea http://orcid.org/0000-0002-6739-0387
Peris, Ketty http://orcid.org/0000-0003-1957-6600
Fargnoli, Maria Concetta http://orcid.org/0000-0002-7249-2556
Esposito, Maria http://orcid.org/0000-0002-4773-6993
Funding for this research was provided by:
Università degli Studi dell’Aquila
Article History
Received: 21 July 2022
Revised: 26 October 2022
Accepted: 16 January 2023
First Online: 7 February 2023
Declarations
:
: A. Chiricozzi served as advisory board member and consultant and has received fees and speaker's honoraria or has participated in clinical trials for AbbVie, Almirall, Leo Pharma, Lilly, Janssen, Novartis, Pfizer, and Sanofi Genzyme. K. Peris has served on advisory boards and received honoraria for lectures from Almirall, Abbvie, Lilly, Galderma, Leo Pharma, Pfizer, Pierre Fabre, Janssen, Novartis, Sanofi, Sun Pharma. MC Fargnoli has served on advisory boards, received honoraria for lectures and research grants from AMGEN, Almirall, Abbvie, BMS, Galderma, Kyowa Kyrin, Leo Pharma, Pierre Fabre, UCB, Lilly, Pfizer, Janssen, MSD, Novartis, Sanofi-Regeneron, Sunpharma. M. Esposito has served as a speaker/board member for Abbvie, Almirall, Biogen, Celgene, Eli Lilly, Janssen, Leo Pharma, Novartis. F. Salfi, G. Amicucci, M. Ferrara, D. Tempesta, A. De Berardinis declared no conflicts of interests.